ABSTRACT
Background Circulating tumor cells (CTCs) have historically been used for prognostication in oncology. We evaluate performance of liquid biopsy CTC assay as a diagnostic tool in suspected pancreaticobiliary cancers. The assay utilises functional enrichment of CTCs followed by immunofluorescent profiling of organ specific markers.
Methods Multicentric case control study was followed by a prospective observational study. Adult patients undergoing tissue sampling for suspected pancreaticobiliary cancer were included in the studies. Blood samples for TruBlood® CTC assay were drawn before tissue sampling. Patients with a prior cancer treatment or cancer history were excluded. CTCs and their clusters were harvested by a unique functional enrichment method which is label-free, size independent and non-mechanical. The CTCs then underwent immunofluorescent profiling for CA19.9, Maspin, EpCAM, CK and CD45, blinded to the tissue histopathological diagnosis. TruBlood® malignant or non-malignant predictions were compared with tissue diagnoses to establish the sensitivity and specificity.
Results The case-control study evaluated 360 participants including 188 cases diagnosed with pancreaticobiliary cancer and 172 healthy individuals. A subsequent prospective observational study included 88 individuals with suspicion of pancreaticobiliary malignancy. The test had 95.9% overall sensitivity (95% CI: 86.0% - 99.5%) and 92.3% specificity (95% CI: 79.13% to 98.38%) to differentiate pancreaticobiliary cancers (PBC) (n = 49) from benign PB conditions (n = 39).
Conclusions The high accuracy of the CTC based TruBlood test demonstrates its potential clinical application as a diagnostic tool to assist effective detection of pancreaticobiliary cancers when tissue sampling is unviable or inconclusive. A confirmational prospective interventional studiy in patients with suspicion of pancreaticobiliary malignancy including those with unavailability of tissue diagnosis is warranted.
Competing Interest Statement
AG, NR, AdS and RA declare no COI. SAL declares COI in the form of consulting role, advisory role, speakers bureau as well as stock and other ownership interests with entities and organizations not associated with the current study. DA, VD, AjS and DP are full time employees of the Study Sponsor.
Funding Statement
No external funding was obtained for this study. The entire study was funded by the Study Sponsor (DCG).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All studies with human participants were approved by an Ethics Committee of the study sponsor and / or the participating site. The Institutional Ethics Committee (IEC) of Datar Cancer Genetics (DCG, sponsor) gave ethical approval for the TRUEBLOOD and RESOLUTE studies. The CTC-based Cancer Detection and Diagnosis Study was approved by the site ECs including Health Point Hospital (site), Krishna Institute of Medical Sciences (site) as well as an independent EC, viz., Royal Pune Independent Ethics Committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
ABBREVIATIONS
- %
- Percent
- Ab
- Antibodies
- AD
- Adenocarcinoma
- CA19.9
- Cancer Antigen 19.9
- CAP
- College of American Physicians
- CD45
- Common Leucocyte Antigen
- CEA
- Carcinoembryonic Antigen
- CEM
- CTC Enrichment Medium
- CI
- Confidence Interval
- CK
- Cytokeratin
- CLIA
- Clinical Laboratory Improvement Amendments
- CT
- Computed Tomography
- CTC
- Circulating Tumor Cell
- ddPCR
- Droplet Digtal Polymerase Chain Reaction
- DCG
- Datar Cancer Genetics
- EC
- Ethics Committee
- EpCAM
- Epithelial Cell Adhesion Molecule
- ERCP
- Endoscopic Retrograde Cholangiopancreatography
- EUS
- Endoscopic Ultrasound
- FNAC
- Fine Needle Aspiration Cytology
- gDNA
- Genomic DNA
- HPE
- Histopathological examination
- ICC
- Immunocytochemistry
- IEC
- Institutional Ethics Committee
- IgG
- Immunoglobulin G
- LoB
- Limit of Blank
- LoD
- Limit of Detection
- MRCP
- Magnetic Resonance Cholangiopancreatography
- Maspin
- Mammalian serine proteinase inhibitor
- NGS
- Next Generation Sequencing
- NET
- Neuroendocrine Tumors
- PB
- Pancreaticobiliary
- PBC
- Pancreaticobiliary cancers
- RBC
- Red Blood Cells
- STR
- Short Tandem Repeat
- STROBE
- Strengthening the Reporting of Observational Studies in Epidemiology
- USG
- Ultrasonography
- USPSTF
- United States Preventive Services Task Force
- WBC
- White Blood Cells;
